IL-6 Drug Promising in Depression; U.S. More Anxious; AI Risks in Addiction Medicine

(MedPage Today) -- A single infusion of the interleukin (IL)-6 inhibitor tocilizumab (Actemra) showed greater improvements in depression severity, somatic symptoms, fatigue, and anxiety in patients with difficult-to-treat depression and low-grade...
Source
MedPage Today
Opens original article in a new tab



